NCT02360657 - Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 16, 2015

Primary Completion Date

September 8, 2015

Study Completion Date

September 8, 2015

Conditions

Alzheimer's Disease

Interventions

DRUG

JNJ-54861911, 10 mg

JNJ-54861911, 10 mg (2\*5 mg tablet) orally once daily for 4 weeks.

DRUG

JNJ-54861911, 50 mg

JNJ-54861911, 50 mg (2\*25 mg tablet) orally once daily for 4 weeks.

DRUG

Placebo

Placebo matching to JNJ-54861911 tablet orally once daily for 4 weeks.

Trial Locations (2)

Fukuoka

Tokyo